[HTML][HTML] A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher, C Aylesworth, J Rizzo, E Izbicka… - Annals of oncology, 2000 - Elsevier
Background Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
[PDF][PDF] A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher, C Aylesworth, J Rizzo, E Izbicka… - Annals of …, 2000 - Citeseer
Summary Background; Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that
inhibits microtubule assembly and also depolymerizes preformed microtubules. In …
inhibits microtubule assembly and also depolymerizes preformed microtubules. In …
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher, C Aylesworth, J Rizzo… - Annals of …, 2000 - annalsofoncology.org
Background Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher, C Aylesworth, J Rizzo, E Izbicka… - Annals of …, 2000 - elibrary.ru
Background: Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
[PDF][PDF] A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher, C Aylesworth, J Rizzo, E Izbicka… - Annals of …, 2000 - researchgate.net
Summary Background; Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that
inhibits microtubule assembly and also depolymerizes preformed microtubules. In …
inhibits microtubule assembly and also depolymerizes preformed microtubules. In …
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher, C Aylesworth, J Rizzo, E Izbicka… - Annals of …, 2000 - infona.pl
Background: Rhizoxin (NSC 332598) is a novel macrolide antitumorantibiotic that inhibits
microtubule assembly and also depolymerizes preformedmicrotubules. In preclinical …
microtubule assembly and also depolymerizes preformedmicrotubules. In preclinical …
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors.
AW Tolcher, C Aylesworth, J Rizzo… - Annals of Oncology …, 2000 - europepmc.org
Background Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher, C Aylesworth, J Rizzo… - Annals of oncology …, 2000 - pubmed.ncbi.nlm.nih.gov
Background Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
microtubule assembly and also depolymerizes preformed microtubules. In preclinical …
[引用][C] A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW TOLCHER, C AYLESWORTH, J RIZZO… - Annals of …, 2000 - pascal-francis.inist.fr
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in
patients with advanced solid tumors CNRS Inist Pascal-Francis CNRS Pascal and Francis …
patients with advanced solid tumors CNRS Inist Pascal-Francis CNRS Pascal and Francis …